Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. OMER
OMER logo

OMER Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Omeros Corp (OMER) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
13.250
1 Day change
-1.41%
52 Week Range
17.650
Analysis Updated At
2026/04/17
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Omeros Corp (OMER) is not a strong buy for a beginner investor with a long-term strategy at this moment. Despite some bullish technical indicators, the lack of significant positive financial performance, no recent news catalysts, and weak stock trend projections make it less compelling as a long-term investment. Holding off for now is recommended.

Technical Analysis

The MACD is positive and expanding, indicating bullish momentum. The RSI is neutral at 73.02, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level (R1: 12.363) with a pre-market price of 12.71, suggesting limited immediate upside potential.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

The low put-call ratios indicate a bullish sentiment in the options market. However, implied volatility is relatively high (82.01), suggesting potential price swings.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
4
Buy
9

Positive Catalysts

  • Hedge funds are heavily buying, with a significant increase of 185085.19% in the last quarter. Technical indicators show bullish momentum.

Neutral/Negative Catalysts

  • No recent news or event-driven catalysts. Financial performance in the latest quarter is weak, with a significant drop in net income (-375.69% YoY) and EPS (-325.93% YoY). Stock trend analysis predicts a negative performance in the next week (-1.18%) and month (-12.74%).

Financial Performance

In 2025/Q4, revenue remained at 0 with no growth. Net income dropped significantly to -$86.45M (-375.69% YoY), and EPS fell to 1.22 (-325.93% YoY). Gross margin remained at 0 with no improvement.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst rating or price target updates are available for OMER.

Wall Street analysts forecast OMER stock price to rise
4 Analyst Rating
Wall Street analysts forecast OMER stock price to rise
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 13.440
sliders
Low
36
Averages
43.67
High
55
Current: 13.440
sliders
Low
36
Averages
43.67
High
55
H.C. Wainwright
Brandon Folkes
maintain
$20 -> $40
AI Analysis
2026-01-08
Reason
H.C. Wainwright
Brandon Folkes
Price Target
$20 -> $40
AI Analysis
2026-01-08
maintain
Reason
H.C. Wainwright analyst Brandon Folkes raised the firm's price target on Omeros to $40 from $20 and keeps a Buy rating on the shares. The firm cites the approval of Yartemlea for hematopoietic stem cell transplant-associated thrombotic microangiopathy for the target boost. The analyst views the approval as a "critical inflection point" for Omeros.
H.C. Wainwright
H.C. Wainwright
Buy
maintain
$20
2025-12-24
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$20
2025-12-24
maintain
Buy
Reason
H.C. Wainwright reiterated a Buy rating and $20 price target on Omeros following the FDA approval of Yartemlea for hematopoietic stem cell transplant-associated thrombotic microangiopathy. The firm sees the Yartemlea approval as a "significant validation" of Omeros value. H.C. Wainwright's current model assumed an 80% probability of success for Yartemlea in the U.S., and pricing of $150K per patient.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for OMER
Unlock Now

People Also Watch